# A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

> **NCT03250273** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 44 (actual)

## Conditions studied

- Metastatic Cholangiocarcinoma
- Cholangiocarcinoma
- Pancreatic Cancer
- Metastatic Pancreatic Cancer
- Unresectable Pancreatic Cancer
- Unresectable Cholangiocarcinoma

## Interventions

- **DRUG:** Entinostat
- **DRUG:** Nivolumab
- **DRUG:** Entinostat
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03250273
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-06
- **Primary completion:** 2020-11-20
- **Final completion:** 2020-11-20
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-05-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03250273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03250273, "A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03250273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*